Tired-eye supplement introduced at the American Optometric Association

Article

At the recent American Optometric Association annual congress, Astavita Professional introduced astaxanthin (AstaREAL, Fuji Health Science) for the relief and prevention of asthenopia.

Key Points

Burlington, NJ-At the recent American Optometric Association annual congress, Astavita Professional introduced astaxanthin (AstaREAL, Fuji Health Science) for the relief and prevention of asthenopia.

Asthenopia is characterized by sensitivity to glare, headaches, sore eyes, and blurred vision. Fuji Chemical Industry of Japan's 11 human clinical studies of an all-natural antioxidant-astaxanthin-have shown significant positive results against asthenopia.

Astaxanthin acts as both a lipid-soluble and water-soluble antioxidant to reduce cellular inflammation while protecting cells. Supporting studies have shown that astaxanthin increases capillary blood flow and improves ciliary body function, as well as increases the endurance and recovery of muscles after overuse, exercise, and other forms of stress.

Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.